IRLAB says WHO assigns generic name linepemat to Parkinson’s apathy drug candidate in Phase Ib trial

Reuters2026/08/19 05:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IRLAB Therapeutics announced WHO assigned IRL757 the generic name linepemat, supporting its positioning as a distinct drug candidate.
Linepemat is being evaluated in the Phase Ib LIFT-PD study for apathy linked to Parkinson’s disease, an area with no approved drug treatments.
Clinical results have not been presented; first LIFT-PD readout is scheduled for mid-2027.
The program remains under IRLAB’s ownership; Otsuka is funding the trial, with an option to broaden the collaboration later.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IRLAB says WHO assigns generic name linepemat to Parkinson’s apathy drug candidate in Phase Ib trial

You may also like

Crypto prices